When 19-year-old Maya swallowed the small vibrating capsule at UCLA Medical Center, she wasn’t just participating in a study—she was helping unlock a hidden layer of anorexia nervosa that blood tests and body mass indexes can’t see. Inside her stomach, the pill sent gentle pulses researchers used to measure how her brain responded to internal bodily signals—a window into the gut-brain connection that could predict whether she, and thousands like her, might relapse after treatment. Anorexia nervosa, a condition with the highest mortality rate of any psychiatric disorder, affects over 30 million people in the U.S. alone and carries a relapse rate of up to 50% within a year of weight restoration. But now, thanks to a groundbreaking study led by Dr. Sahib Khalsa at UCLA Health, doctors may finally have an objective tool to assess recovery beyond the scale.
For decades, treatment has focused on weight gain as the primary marker of progress. Yet many patients continue to struggle with distorted body image and disordered eating behaviors long after reaching a healthy weight. The reason, Khalsa’s team suspected, might lie in how the brain processes signals from the gut. To test this, they recruited 62 women and girls hospitalized with anorexia whose weight had been restored, along with 57 healthy controls. Participants swallowed the ingestible vibrating capsule, which delivered subtle stomach vibrations while researchers monitored brain activity, heart rate, and stomach rhythms. As the vibrations pulsed, participants pressed a button when they felt them—a simple task that revealed profound differences.
The findings were striking: individuals with anorexia were significantly less accurate at detecting stomach sensations. Even when the capsule vibrated, many insisted they felt nothing, and their brains were slower to update that belief when evidence contradicted it. This cognitive bias—expecting not to feel bodily signals and ignoring them when they arrived—persisted despite healthy weight. Crucially, those with the strongest bias were also the most likely to relapse within six months of discharge. Using a computational model, the team showed these gut-brain processing differences weren’t just symptoms; they were predictors.
“This isn’t just about ignoring hunger,” Khalsa explained. “It’s that the nervous system may be wired to distrust the body’s signals altogether.” That insight could transform treatment, offering clinicians a biomarker to identify high-risk patients and tailor therapies that retrain brain-body communication. While the study must be replicated in more diverse populations, the vibrating capsule—already FDA-cleared for other gastrointestinal uses—could be adapted for clinical use in years, not decades. For patients like Maya, that means recovery might one day be measured not just by weight, but by the quiet, steady dialogue between gut and brain finally coming back online.